氯法拉滨在血液系统恶性肿瘤治疗中的应用
被引量:2
摘要
急性白血病是儿童以及成人常见的血液恶性肿瘤之一,近年来由于支持治疗以及化疗方案的改进,在儿童急性淋巴细胞白血病(ALL)5年无病生存(DFS)率达80%以上,急性髓系白血病(AML)5年DFS率达40%,成人ALL患者长期生存率则低于30%。
出处
《中华血液学杂志》
CAS
CSCD
北大核心
2010年第1期66-68,共3页
Chinese Journal of Hematology
参考文献23
-
1Faderl S, Gandhi V, Keating MJ, et al. The role of clofarabine in hematologic and solid malignancies-development of a next-generation nucleoside analog. Cancer, 2005,103 : 1985-1995.
-
2King KM, Damaraju VL, Vickers MF, et al. A comparison of the transportability, and its role in cytotoxicily, of elofarabitle, cladribine, and fludarabine by recombinant human nucleoside transporters produced in three model expression systems. Mol Pharmacol,2006, 69:346-353.
-
3Zhang Y, Zhang J, Shahriar M, et al. Clofarabine induces hypomethylation of DNA and expression of cancer-testis antigens. Blood, 2008,112 : absract 379.
-
4Gandhi V, Kantarjian H, Faderl S, et al. Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemias. Clin Cancer Res, 2003, 9:6335-6342.
-
5Jeha S, Gandhi V, Chan KW, et al. Clofarabine, a novel nucleoside analog, is aetive in pediatric patients with advaneed leukemia. Blood, 2004,103:784-789.
-
6Kantarjian HM, Gandhi V, Kozueh P, et al. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J Clin Oncol, 2003, 21 : 1167-1173.
-
7Kantarjian H, Gandhi V, Cortes J, et al. Phase 2 clinical and pharmacologic study of clofarahine in patients with refractory or relapsed acute leukemia. Blood, 2003,102:2379-2386.
-
8Jeha S, Gaynon PS, Razzouk BI, et al. Phase Ⅱ study of elofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J Clin Oncol, 2006,24: 1917-1923.
-
9Faded S, Gandhi V, O' Brien S, et al. Results of a phase 1-2 study of clofarabine in combination with evtarabine (ara-C) in relapsed and refraetory acute leukemias. Blood, 2005,105: 940- 947.
-
10Becker PS, Estey E, Petersdorf S, et al. Phase Ⅰ trial of clofarabine and high dose cytarabine with G-CSF priming (G-CLAC) for relapsed or refractory acute myeloid leukemia. Blood, 2005, 112 : absract 2964.
同被引文献35
-
1夏敏,蒋慧.儿童急性白血病治疗新药氯法拉滨[J].世界临床药物,2007,28(6):356-359. 被引量:11
-
2Pui CH, Jeha S, Kirkpatrick P. Clofarabine [ J]. Nat Rev Drug Discov, 2005, 4 (5) : 369-370.
-
3Tallman MS. New agents for the treatment of acute myeloid leukemia [ J ]. Best Pract Res Clin Haematol, 2006, 19 (2) : 311- 320.
-
4Lindemalm S, Liliemark J, Juliusson G, et al. Cytotoxieity and pharmacokineties of eladribine metabolite, 2-ehloroadenine in patients with leukemia [J]. Cancer Lett, 2004, 210 ( 2 ) : 171- 177.
-
5Zhenchuk A, Lotfi K, Juliusson G, et al. Mechanisms of anticancer action and pharmacology of clofarabine [ J ]. Biochem Pharmacol, 2009, 78(11 ): 1351-1359.
-
6Bonate PL, Arthaud L, Cantrell WR Jr, et al. DiscovexT and development of clofarabine: a nueleoside analogue for treating cancer [J]. Nat Rev Drug Discov, 2006, 5(10): 855-863.
-
7Reichelova V, Liliemark J, Albertioni F, et al. Liquid chromatographic study of acid stability of 2-chloro-2'-arabino- fluoro- 2'-deoxyadenosine, 2-chloro-2'-deoxyadenosine and related analogues [ J].J Pharm Biomed Anal, 1995, 13 (4-5) : 711-714.
-
8Xie C, Plunkett W. Metabolism and actions of 2-ehloro-9-(2-deoxy-2- fluoro-beta-D-arabinofuranosyl)-adenine in human lymphoblastoid cells[J]. Cancer Res, 1995, 55(13): 2847-2852.
-
9King KM, Damaraju VL, Vickers MF, et al. A comparison of the transportability, and its role in cytotoxicity, of clofarabine, cladribine, and fludarabine by recombinant human nucleoside transporters produced in three model expression systems [Jl. Mol Pharmacol, 2006, 69 ( 1 ) : 346-353.
-
10Chen LS, Plunkett W, Gandhi V. Polyadenylation inhibition by the triphosphates of deoxyadenosine analogues [ J ]. Leuk Res, 2008, 32(10) : 1573-1581.
二级引证文献5
-
1林燕琴,陈忠,徐敏华,赵学清,章卫忠,陈志航.顶空气相色谱法测定氯法拉滨中有机溶剂残留量[J].今日药学,2013,23(11):727-729.
-
2胡贤娇,殷小成,王萍,彭艳辉,罗永姣.二烯丙基二硫上调Beclin1介导白血病K562细胞自噬性死亡的研究[J].现代生物医学进展,2014,14(14):2606-2609. 被引量:4
-
3蒋卉男,胡荣,刘卓刚.自噬与白血病治疗研究最新进展[J].中国实验血液学杂志,2015,23(1):290-294. 被引量:8
-
4许文锋,冯晓勤,李春富,吴学东,何岳林,张玉明,裴夫瑜.西罗莫司诱导急性髓系白血病U937细胞白噬及凋亡[J].中华实用儿科临床杂志,2015,30(17):1336-1340. 被引量:2
-
5曹强强,殷小成,肖亮,肖正香.沉默UVRAG对白血病K562/ADM细胞自噬及耐药性的影响[J].肿瘤基础与临床,2016,29(3):185-190.
-
1锁盼,张乐萍,吴珺,陆爱东,王彬,左英熹,程翼飞,刘桂兰.氯法拉滨治疗儿童复发/难治性急性淋巴细胞性白血病的疗效分析[J].中国当代儿科杂志,2013,15(6):444-447. 被引量:1
-
2李程亮,刘海波,张梅,贺鹏程.氯法拉滨诱导U937细胞自噬性死亡的机制[J].中国实验血液学杂志,2013,21(2):347-350. 被引量:4
-
3刘海波,张梅,李呈亮,贺鹏程.氯法拉滨对NB4细胞的增殖抑制作用及对Bcl-2表达的影响[J].中国实验血液学杂志,2012,20(3):571-573. 被引量:3
-
4李志军,伍国顺,李爱珠.小剂量三氧化二砷联合化疗治疗血液恶性肿瘤的临床疗效观察[J].广西医学,2004,26(9):1312-1313. 被引量:3
-
5乔静,陈秀华.沙利度胺的研究及临床应用新进展[J].国际药学研究杂志,2008,35(4):256-260. 被引量:5
-
6张玉平.抗真菌治疗的肾脏安全性[J].继续医学教育,2011,25(7):81-82.
-
7孟岩,于洁.氯法拉滨在儿童白血病治疗中的应用[J].儿科药学杂志,2011,17(4):52-55. 被引量:1
-
8聂颖兰,傅得兴,胡欣,王唯红.新型抗白血病药氯法拉滨[J].中国新药杂志,2007,16(10):821-824. 被引量:9
-
9许正年.替吉奥联合紫杉醇治疗进展期胃癌的疗效和安全性分析[J].中国处方药,2014,12(8):59-60. 被引量:1
-
10刘庭波,祝亮方,战榕,吕联煌,胡建达.两性霉素B治疗49例血液恶性肿瘤患者深部真菌感染分析[J].中国感染与化疗杂志,2007,7(1):38-40. 被引量:9